Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c vs trastuzumab + vinorelbine/capecitabine in HER2-positive advanced breast cancer (third-line and beyond)
CTR20231487Phase 3Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of DP303c in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2023; status: terminated.
02
Drugs
DP303c
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20231487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231487.